Article

Gilenya is the first FDA-approved drug for the treatment of multiple sclerosis (MS) in pediatric patients. Earlier it was approved in 2010 to treat adult patients with relapsing MS.

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Register with your email to read the full article.

This article is FREE for you! Unlock the unlimited access by subscribing to Medgenera All-Access.

More in DRUG TRIAL


DRUG TRIAL

FDA Approves First Therapy ‘Gilenya’ for Children with Multiple Sclerosis

Gilenya is the first FDA-approved drug for the treatment of multiple sclerosis (MS) in pediatric patients. Earlier it was approved in 2010 to treat adult patients with relapsing MS.

Most Popular


GROW

7 New Ideas to Start a Healthcare Business in India (2018)

Highlights Herein, we are proposing the seven new healthcare business ideas in India in 2018 which are based on our ...

NEWLY PUBLISHED

Pharma Patents: Can India Reward Incremental Innovation?

Chandramouli Natarajan is an Associate Scientist, Ricon pharma LLC, Denville, USA. He has presented his opinion and views on the Pharmaceutical patents issues in India. This article is available for free to read and share.

Leave a reply